Back to resultsEffect of Partial Dietary Replacement From Animal to Plant-Based Protein for Type 2 Diabetes Management
Primary Purpose
Type 2 Diabetes, Overweight, Obesity
Status
Recruiting
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
Control Diet
Plant-based Diet
Sponsored by
About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Diabetes Mellitus, Obesity, Plant-based Diet, Insulin Resistance
Eligibility Criteria
Inclusion Criteria: Adults (≥18 and ≤65 years old) Diagnosis of Type 2 Diabetes; Glycated hemoglobin from 7% to 11%; Overweight or obesity (BMI ≥25 kg/m² and <40 kg/m²); Use of any hypoglycemic and insulin; Stable weight (maximum variation of approximately 5%) for at least 12 weeks before screening; Not having undergone dietary intervention in the last 6 months; Have the ability to understand and be able to adhere to intervention proposals; Able and willing to provide an informed consent form for written and to comply with the requirements of the study protocol; Exclusion Criteria: Type 1 diabetes mellitus; Retinopathy with vision deficit that limits the activities proposed in the interventions; Chronic kidney disease with estimated glomerular filtration < 30 mL/min per 1.73m²; Liver failure, chronic viral hepatitis; Grade III or IV heart failure Active or progressive neurodegenerative disease; Prior stroke that has caused sequelae; Use of medications that affect glucose metabolism (e.g. corticosteroids or immunosuppressants) or cause weight loss; Chronic treatment with oral or parenteral corticosteroids (>7 days consecutive treatment) within 4 weeks prior to screening; Treatment with weight-reducing agents (eg, orlistat, sibutramine, topiramate, bupropion, liraglutide, semaglutide) within the last 12 weeks before screening; Treatment with thyroid hormone that was not maintained at a stable dose in last 12 weeks before screening; History of active substance abuse (including alcohol) within the last year; Thyroid Stimulating Hormone (TSH) outside the normal range; Fasting triglycerides ≥ 600 mg/dL; Tumor diagnosed and/or treated (except basal cell skin cancer, carcinoma in situ of the cervix, or prostate cancer in situ) within the last 5 years; Severe psychiatric illness; Predisposition or diagnosis of eating disorders; Women who are pregnant, intend to become pregnant during the study period, or who are currently breastfeeding; Hyperglycemia characterized by acute symptoms: polyuria, polydipsia and/or weight loss in the last 3 months; Metabolic and acute complications of diabetes such as ketoacidosis or hyperosmolar coma; Potentially unreliable patients and those deemed by the investigator to be unsuitable for the study; Night workers who work after 10pm; Being on a vegetarian, vegan or flexitarian diet at the time of recruitment; Having undergone bariatric surgery; Carriers of the human immunodeficiency virus (HIV); Any other medical condition/disorder that the investigators consider that are likely to: interfere with the patient's ability to complete the entire study period or participate in study activities; Participants who require any treatment that could affect the interpretation, reliability or safety of data during the study intervention.
Sites / Locations
- Hospital de Clínicas de Porto AlegreRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Control
Intervention
Arm Description
Hypocaloric diet with predominance of animal protein
Hypocaloric diet with predominance of plant protein
Outcomes
Primary Outcome Measures
Change in Glycated Hemoglobin
Difference between groups in glycated hemoglobin
Secondary Outcome Measures
Glycemic Variability
For continuous glucose monitoring and assessment of glycemic variability, the FreeStyle Libre, ABBOTT® device will be used. FreeStyle Libre consists of a continuous glucose monitoring (SMCG) system. Glycemic variability will be assessed using time on target parameters of values between 70 and 180 mg/dL, time in hypoglycemia and time above target and coefficient of variability as measures of glycemic variability.
Changes in postprandial metabolism
Postprandial metabolism will be measured after the intake of liquid standard meal. Insulin secretion, insulin sensitivity and beta-cell function will be assessed by mathematical models
Changes in body composition
Fat-free mass and fat mass will be assessed by Bioelectrical Impedance (body composition analyzer tetrapolar InBody 370S, BiospaceCo. Ltd, Seoul, South Korea). Anthropometric measures include brachial, neck, waist, hip and calf circumferences, with participants wearing light clothing and barefoot.
Changes in cardiometabolic outcomes
Lipid profile will include total cholesterol, HDL-c, LDL-c, triglycerides, apolipoprotein B, apolipoprotein a1 and lipoprotein (a).
Changes in blood pressure
Blood pressure (mmHg) will be assessed in triplicate with an interval of 1 minute between measurements, with the participant in the sitting position, after 5 minutes of rest. On a subsample, the ambulatory blood pressure monitoring will be used in order to record blood pressure measures in 24 hours and evaluate parameters such as mean BP, pressure loads, areas under the curve, variations between daytime and nighttime, pulse pressure variability
Changes in inflammatory marker
Ultra-Sensitive C-Reactive Protein (US-CRP) test will be performed to assess systemic inflammation.
Changes in food craving scale
Food craving will be assessed by the Food Craving Questionnaire-State (FCQ-S), which is composed of 15 statements and is a tool sensitive to changes in contextual, psychological and physiological states in response to specific situations. Higher scores are associated with greater food deprivation, negative eating-related experiences and a greater susceptibility to triggers that lead to eating. Each item has a Likert-response, with (1) totally disagree and (5) totally agree. Total scores vary from 15 to 75 and correspond to the sum of all statements.
Changes in quality of life scale
Quality of life will be measured by the The Short Form 36 Health Survey Questionnaire (the SF-36). SF-36 is a 36 item scale, which measures eight domains of health status: physical functioning (10 items); physical role limitations (four items); bodily pain (two items); general health perceptions (five items); energy/vitality (four items); social functioning (two items); emotional role limitations (three items) and mental health (five items). The scores are transformed to range from zero where the respondent has the worst possible health to 100 where the respondent is in the best possible health.
Changes in depressive symptoms
The Beck Depression Inventory will be used for detecting depressive symptoms, which consists of 21 sets of statements about depressive symptoms in the last 15 days that are rated on a 0 to 3 scale and total scores ranging from 0 to 63. The severity of symptoms will be classified as follows: 0-13, minimal/no depression; 14-19, mild depression; 20-28, moderate depression; and 29-63, severe depression.
Changes in anxiety symptoms
The Generalized Anxiety Symptoms-7 (GAD-7) will be used for assessing anxiety symptoms, which consists of 7 self-reported items. Each item has a Likert-response format on a 4-point scale (0- 3 points). Respondents will be asked to consider the previous 2 weeks and to rate symptom frequency as 'not at all' (0), 'several days' (1), 'more than half of all days' (2) or 'nearly all days' (3). The total score response ranges from 0 to 21.
Adherence to a plant-based diet
Adherence will be assessed by 7-day weighted food records at 12 and 2 weeks, and by 24-hour food records monthly.
Full Information
NCT ID
NCT05706155
First Posted
December 23, 2022
Last Updated
January 20, 2023
Sponsor
Hospital de Clinicas de Porto Alegre
Collaborators
Conselho Nacional de Desenvolvimento Científico e Tecnológico
1. Study Identification
Unique Protocol Identification Number
NCT05706155
Brief Title
Effect of Partial Dietary Replacement From Animal to Plant-Based Protein for Type 2 Diabetes Management
Official Title
Effect of Partial Dietary Replacement From Animal to Plant-Based Protein for Type 2 Diabetes Management: A Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2022 (Actual)
Primary Completion Date
September 30, 2024 (Anticipated)
Study Completion Date
October 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital de Clinicas de Porto Alegre
Collaborators
Conselho Nacional de Desenvolvimento Científico e Tecnológico
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The goal of this clinical trial is to examine the effect plant-based diet, with a partial replacement of animal protein by plant protein, in blood sugar levels and other health risks of people with type 2 diabetes and excessive weight. The plant-based diet will be compared to a standard healthy diet according to guidelines for people with diabetes. Participants will follow a plant-based or a standard healthy diet for 24 weeks and will maintain their habitual levels of physical activity.
Detailed Description
This is a single center, open label, parallel and randomized clinical trial. Subjects with type 2 diabetes (T2D) and excessive weight will be recruited through advertisement on the web page of Hospital de Clínicas de Porto Alegre (HCPA), local newspaper, television and social media, or referred by a doctor or nutritionist, from external to HCPA services. Patients will be also screened through electronic records of HCPA's clinics. After screening and selection according to inclusion criteria, participants will undergo a clinical, laboratory and nutritional evaluation following a standard assessment protocol. After all baseline assessments, they will be randomly allocated to one of the following interventions for 24 weeks: (1) Control diet (CDG): hypocaloric diet according to current guidelines for T2D or (2) Plant-based diet (PBG): hypocaloric diet with partial replacement of animal protein by plant protein. Both groups will have caloric targets calculated to achieve a 5% weight loss during the 6 months of study, will have the same macronutrient distribution on the diet and will receive the same nutritional and medical support. Telephone calls will be performed monthly for adherence evaluation. At the end of 12 and 24 weeks of intervention, all patients will be submitted to the same clinical, laboratory and nutrition exams applied at baseline.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes, Overweight, Obesity
Keywords
Diabetes Mellitus, Obesity, Plant-based Diet, Insulin Resistance
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This is a single center and open label randomized controlled trial, in which participants will be assigned to one of the two different dietary interventions
Masking
None (Open Label)
Masking Description
The participants and the care providers will not be blinded. People involved in data analysis will be blinded.
Allocation
Randomized
Enrollment
140 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Hypocaloric diet with predominance of animal protein
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Hypocaloric diet with predominance of plant protein
Intervention Type
Behavioral
Intervention Name(s)
Control Diet
Intervention Description
Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 45 to 55% of energy from carbohydrates, prioritizing those with low glycemic index; 25 to 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.
Intervention Type
Behavioral
Intervention Name(s)
Plant-based Diet
Intervention Description
Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 45 to 55% of energy from carbohydrates, prioritizing those with a low glycemic index; 25 to 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.
Primary Outcome Measure Information:
Title
Change in Glycated Hemoglobin
Description
Difference between groups in glycated hemoglobin
Time Frame
baseline, 12 and 24 weeks
Secondary Outcome Measure Information:
Title
Glycemic Variability
Description
For continuous glucose monitoring and assessment of glycemic variability, the FreeStyle Libre, ABBOTT® device will be used. FreeStyle Libre consists of a continuous glucose monitoring (SMCG) system. Glycemic variability will be assessed using time on target parameters of values between 70 and 180 mg/dL, time in hypoglycemia and time above target and coefficient of variability as measures of glycemic variability.
Time Frame
baseline and 24 weeks
Title
Changes in postprandial metabolism
Description
Postprandial metabolism will be measured after the intake of liquid standard meal. Insulin secretion, insulin sensitivity and beta-cell function will be assessed by mathematical models
Time Frame
baseline and 24 weeks
Title
Changes in body composition
Description
Fat-free mass and fat mass will be assessed by Bioelectrical Impedance (body composition analyzer tetrapolar InBody 370S, BiospaceCo. Ltd, Seoul, South Korea). Anthropometric measures include brachial, neck, waist, hip and calf circumferences, with participants wearing light clothing and barefoot.
Time Frame
Monthly, up to 24 weeks
Title
Changes in cardiometabolic outcomes
Description
Lipid profile will include total cholesterol, HDL-c, LDL-c, triglycerides, apolipoprotein B, apolipoprotein a1 and lipoprotein (a).
Time Frame
baseline, 12 and 24 weeks
Title
Changes in blood pressure
Description
Blood pressure (mmHg) will be assessed in triplicate with an interval of 1 minute between measurements, with the participant in the sitting position, after 5 minutes of rest. On a subsample, the ambulatory blood pressure monitoring will be used in order to record blood pressure measures in 24 hours and evaluate parameters such as mean BP, pressure loads, areas under the curve, variations between daytime and nighttime, pulse pressure variability
Time Frame
baseline, 12 and 24 weeks
Title
Changes in inflammatory marker
Description
Ultra-Sensitive C-Reactive Protein (US-CRP) test will be performed to assess systemic inflammation.
Time Frame
baseline, 12 and 24 weeks
Title
Changes in food craving scale
Description
Food craving will be assessed by the Food Craving Questionnaire-State (FCQ-S), which is composed of 15 statements and is a tool sensitive to changes in contextual, psychological and physiological states in response to specific situations. Higher scores are associated with greater food deprivation, negative eating-related experiences and a greater susceptibility to triggers that lead to eating. Each item has a Likert-response, with (1) totally disagree and (5) totally agree. Total scores vary from 15 to 75 and correspond to the sum of all statements.
Time Frame
baseline, 12 and 24 weeks
Title
Changes in quality of life scale
Description
Quality of life will be measured by the The Short Form 36 Health Survey Questionnaire (the SF-36). SF-36 is a 36 item scale, which measures eight domains of health status: physical functioning (10 items); physical role limitations (four items); bodily pain (two items); general health perceptions (five items); energy/vitality (four items); social functioning (two items); emotional role limitations (three items) and mental health (five items). The scores are transformed to range from zero where the respondent has the worst possible health to 100 where the respondent is in the best possible health.
Time Frame
baseline, 12 and 24 weeks
Title
Changes in depressive symptoms
Description
The Beck Depression Inventory will be used for detecting depressive symptoms, which consists of 21 sets of statements about depressive symptoms in the last 15 days that are rated on a 0 to 3 scale and total scores ranging from 0 to 63. The severity of symptoms will be classified as follows: 0-13, minimal/no depression; 14-19, mild depression; 20-28, moderate depression; and 29-63, severe depression.
Time Frame
baseline, 12 and 24 weeks
Title
Changes in anxiety symptoms
Description
The Generalized Anxiety Symptoms-7 (GAD-7) will be used for assessing anxiety symptoms, which consists of 7 self-reported items. Each item has a Likert-response format on a 4-point scale (0- 3 points). Respondents will be asked to consider the previous 2 weeks and to rate symptom frequency as 'not at all' (0), 'several days' (1), 'more than half of all days' (2) or 'nearly all days' (3). The total score response ranges from 0 to 21.
Time Frame
baseline, 12 and 24 weeks
Title
Adherence to a plant-based diet
Description
Adherence will be assessed by 7-day weighted food records at 12 and 2 weeks, and by 24-hour food records monthly.
Time Frame
Baseline, 12 and 24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults (≥18 and ≤65 years old)
Diagnosis of Type 2 Diabetes;
Glycated hemoglobin from 7% to 11%;
Overweight or obesity (BMI ≥25 kg/m² and <40 kg/m²);
Use of any hypoglycemic and insulin;
Stable weight (maximum variation of approximately 5%) for at least 12 weeks before screening;
Not having undergone dietary intervention in the last 6 months;
Have the ability to understand and be able to adhere to intervention proposals;
Able and willing to provide an informed consent form for written and to comply with the requirements of the study protocol;
Exclusion Criteria:
Type 1 diabetes mellitus;
Retinopathy with vision deficit that limits the activities proposed in the interventions;
Chronic kidney disease with estimated glomerular filtration < 30 mL/min per 1.73m²;
Liver failure, chronic viral hepatitis;
Grade III or IV heart failure
Active or progressive neurodegenerative disease;
Prior stroke that has caused sequelae;
Use of medications that affect glucose metabolism (e.g. corticosteroids or immunosuppressants) or cause weight loss;
Chronic treatment with oral or parenteral corticosteroids (>7 days consecutive treatment) within 4 weeks prior to screening;
Treatment with weight-reducing agents (eg, orlistat, sibutramine, topiramate, bupropion, liraglutide, semaglutide) within the last 12 weeks before screening;
Treatment with thyroid hormone that was not maintained at a stable dose in last 12 weeks before screening;
History of active substance abuse (including alcohol) within the last year;
Thyroid Stimulating Hormone (TSH) outside the normal range;
Fasting triglycerides ≥ 600 mg/dL;
Tumor diagnosed and/or treated (except basal cell skin cancer, carcinoma in situ of the cervix, or prostate cancer in situ) within the last 5 years;
Severe psychiatric illness;
Predisposition or diagnosis of eating disorders;
Women who are pregnant, intend to become pregnant during the study period, or who are currently breastfeeding;
Hyperglycemia characterized by acute symptoms: polyuria, polydipsia and/or weight loss in the last 3 months;
Metabolic and acute complications of diabetes such as ketoacidosis or hyperosmolar coma;
Potentially unreliable patients and those deemed by the investigator to be unsuitable for the study;
Night workers who work after 10pm;
Being on a vegetarian, vegan or flexitarian diet at the time of recruitment;
Having undergone bariatric surgery;
Carriers of the human immunodeficiency virus (HIV);
Any other medical condition/disorder that the investigators consider that are likely to: interfere with the patient's ability to complete the entire study period or participate in study activities;
Participants who require any treatment that could affect the interpretation, reliability or safety of data during the study intervention.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Fernando Gerchman, PhD
Phone
+555133596246
Email
fgerchman@hcpa.edu.br
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fernando Gerchman, PhD
Organizational Affiliation
Hospital de Clínicas de Porto Alegre
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital de Clínicas de Porto Alegre
City
Porto Alegre
State/Province
Rio Grande Do Sul
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Fernando Gerchman, PhD
Phone
55 51 33598127
Email
fgerchman@hcpa.edu.br
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
30487971
Citation
Toumpanakis A, Turnbull T, Alba-Barba I. Effectiveness of plant-based diets in promoting well-being in the management of type 2 diabetes: a systematic review. BMJ Open Diabetes Res Care. 2018 Oct 30;6(1):e000534. doi: 10.1136/bmjdrc-2018-000534. eCollection 2018.
Results Reference
background
PubMed Identifier
30660336
Citation
Willett W, Rockstrom J, Loken B, Springmann M, Lang T, Vermeulen S, Garnett T, Tilman D, DeClerck F, Wood A, Jonell M, Clark M, Gordon LJ, Fanzo J, Hawkes C, Zurayk R, Rivera JA, De Vries W, Majele Sibanda L, Afshin A, Chaudhary A, Herrero M, Agustina R, Branca F, Lartey A, Fan S, Crona B, Fox E, Bignet V, Troell M, Lindahl T, Singh S, Cornell SE, Srinath Reddy K, Narain S, Nishtar S, Murray CJL. Food in the Anthropocene: the EAT-Lancet Commission on healthy diets from sustainable food systems. Lancet. 2019 Feb 2;393(10170):447-492. doi: 10.1016/S0140-6736(18)31788-4. Epub 2019 Jan 16. No abstract available. Erratum In: Lancet. 2019 Feb 9;393(10171):530. Lancet. 2019 Jun 29;393(10191):2590. Lancet. 2020 Feb 1;395(10221):338. Lancet. 2020 Oct 3;396(10256):e56.
Results Reference
background
PubMed Identifier
9583841
Citation
Moulin CC, Tiskievicz F, Zelmanovitz T, de Oliveira J, Azevedo MJ, Gross JL. Use of weighed diet records in the evaluation of diets with different protein contents in patients with type 2 diabetes. Am J Clin Nutr. 1998 May;67(5):853-7. doi: 10.1093/ajcn/67.5.853.
Results Reference
background
PubMed Identifier
8137688
Citation
Tai MM. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care. 1994 Feb;17(2):152-4. doi: 10.2337/diacare.17.2.152.
Results Reference
background
PubMed Identifier
21527118
Citation
Czerwoniuk D, Fendler W, Walenciak L, Mlynarski W. GlyCulator: a glycemic variability calculation tool for continuous glucose monitoring data. J Diabetes Sci Technol. 2011 Mar 1;5(2):447-51. doi: 10.1177/193229681100500236.
Results Reference
background
PubMed Identifier
24402217
Citation
Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Braz J Psychiatry. 2013 Oct-Dec;35(4):416-31. doi: 10.1590/1516-4446-2012-1048. Epub 2013 Dec 23.
Results Reference
background
PubMed Identifier
25908249
Citation
Sousa TV, Viveiros V, Chai MV, Vicente FL, Jesus G, Carnot MJ, Gordo AC, Ferreira PL. Reliability and validity of the Portuguese version of the Generalized Anxiety Disorder (GAD-7) scale. Health Qual Life Outcomes. 2015 Apr 25;13:50. doi: 10.1186/s12955-015-0244-2.
Results Reference
background
PubMed Identifier
27288149
Citation
Queiroz de Medeiros AC, Campos Pedrosa LF, Hutz CS, Yamamoto ME. Brazilian version of food cravings questionnaires: Psychometric properties and sex differences. Appetite. 2016 Oct 1;105:328-33. doi: 10.1016/j.appet.2016.06.003. Epub 2016 Jun 7.
Results Reference
background
PubMed Identifier
23827895
Citation
Cruz LN, Fleck MP, Oliveira MR, Camey SA, Hoffmann JF, Bagattini AM, Polanczyk CA. Health-related quality of life in Brazil: normative data for the SF-36 in a general population sample in the south of the country. Cien Saude Colet. 2013 Jul;18(7):1911-21. doi: 10.1590/s1413-81232013000700006.
Results Reference
background
Learn more about this trial
Effect of Partial Dietary Replacement From Animal to Plant-Based Protein for Type 2 Diabetes Management
We'll reach out to this number within 24 hrs